Neoadjuvant immunotherapy → response-adapted adjuvant
Treat before surgery, look at the removed tumour, and only continue treatment if the response was incomplete.
NADINA's design: two neoadjuvant cycles, surgery, then adjuvant therapy only for partial or non-responders. Sixty percent of patients avoided a year of adjuvant treatment. SWOG S1801 showed the same drug works better given partly before surgery.
Pages like this
not linked directly; found by shared links- IdeaTreat the draining lymph node before removing it
Shares Major pathological response (MPR), Sentinel lymph node biopsy, Ipilimumab, Nivolumab.
- TrialKEYNOTE-006
Shares Ipilimumab, Pembrolizumab, Melanoma, Immune checkpoint inhibitors.
- PersonChristian Blank
Shares NADINA, Ipilimumab, Nivolumab, Melanoma.
- TermImmune-related endocrinopathies (thyroiditis, hypophysitis)
Shares Ipilimumab, Nivolumab, Pembrolizumab, Immune checkpoint inhibitors.
- PairingImmunotherapy first, then BRAF/MEK (BRAF-mutant melanoma)
Shares Ipilimumab, Nivolumab, Melanoma, Immune checkpoint inhibitors.
- InstitutionDartmouth Cancer Center
Shares Ipilimumab, Nivolumab, Melanoma, Immune checkpoint inhibitors.
- IdeaRandomised trials of stopping immunotherapy after one year versus continuing
Shares Nivolumab, Pembrolizumab, Melanoma, Immune checkpoint inhibitors.
- PersonTasuku Honjo
Shares Nivolumab, Pembrolizumab, Melanoma, Immune checkpoint inhibitors.